Search
Clinician Ordering Portal
Frequently Asked Questions
Below is the summary of the AltheaDx randomized controlled trial that showed using IDgenetix® improved patient’s clinical outcomes with statistical significance.
The IDgenetix® Advantage The IDgenetix® Testing Process Consists of Three Important Steps Obtaining therapeutic benefit from a medication is dependent on the functioning of metabolic enzymes and key transporter and receptor proteins at the biological site of action. Each IDgenetix test analyzes genes and gene mutations with a demonstrated role in influencing medication response, including efficacy or adverse events. IDgenetix testing provides tailored treatment recommendations for each patient by utilizing our bioinformatic algorithm to integrate patient specific health information with comprehensive genetic results.
The majority of people tested with TissueCypher receive a low-risk score, which is expected because most Barrett’s esophagus patients don’t progress to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC). A high-risk score gives your healthcare provider an opportunity to align your treatment to your predicted risk of progression, to escalate care and intervene early.
TissueCypher provides a risk score and probability of development of high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) within five years. In a recent study by the Mayo Clinic, TissueCypher was shown to independently predict increased risk of progression to HGD/EAC and was also shown to be a stronger predictor of progression than other traditional risk factors like age, sex, segment length, and even expert pathology. Multiple published studies have shown that TissueCypher has a higher positive predictive value than these traditional risk factors, e.g., patients who receive a TissueCypher high-risk score progress at a higher rate than patients with confirmed low-grade dysplasia.
DecisionDx-UM results provide critical prognostic information for you and your doctor to determine the most appropriate plan for monitoring for metastatic disease and potential treatment. While the test cannot, at this point, guide your doctor toward a specific treatment, recent studies show that the results are being used to develop personalized monitoring plans based on a patient’s metastatic risk, initiate referral to a medical oncologist for treatment planning, and refer appropriate high-risk patients to clinical trials.
The DecisionDx-UM test can only be ordered by your physician or other appropriate healthcare provider—usually an ocular oncologist, retinal specialist, or ophthalmologist. Currently, a majority of ocular oncology specialists in the country offer DecisionDx-UM to their patients. If your doctor does not perform the test and you would like further information, you can call Castle Biosciences customer service at 866-788-9007 option #1.
No. Only healthcare professionals (physician, physician assistants, or nurse practitioner) can order a test from Castle Biosciences. If you need help finding a healthcare professional who can order the test for you, please contact our customer service team at 866-788-9007 or email us..
Castle Biosciences operates clinical laboratories in Phoenix and Pittsburgh. The Company’s laboratories are College of American Pathologists (CAP) accredited and Clinical Laboratory Improvement Amendments (CLIA) certified, reflecting the Company’s commitment to high-quality standards and excellence in patient care. Castle's laboratories are licensed to perform tests throughout the United States.
Castle Biosciences works with all insurance providers, including Medicare, commercial insurers, and the VA, to secure payment coverage for tests. Castle will submit insurance claims and manage the insurance billing process on behalf of patients. The company also sponsors an industry-leading Patient Assistance Program with the belief that quality care should not depend on financial considerations.
Molecular diagnostic testing is a fast-growing field, so your healthcare professional may not know about all of the tests that are now available. If your healthcare professional is interested in more information, please ask them to contact us at 866-788-9007.